TrivarX Limited (AU:TRI)
ASX:TRI
Want to see AU:TRI full AI Analyst Report?
TRI Stock Chart & Stats
AU$0.02
<AU$0.01(6.67%)
At close: 4:00 PM EST
AU$0.02
<AU$0.01(6.67%)
Day’s Range― - ―
52-Week Range<AU$0.01 - AU$0.04
Previous CloseN/A
Volume87.40K
Average Volume (3M)1.22M
Market Cap
AU$25.38M
Enterprise ValueAU$25.46M
Total Cash (Recent Filing)AU$1.25M
Total Debt (Recent Filing)AU$169.03K
Price to Earnings (P/E)―
Beta2.54
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding1,153,693,500
10 Day Avg. Volume1,871,965
30 Day Avg. Volume1,217,195
Financial Highlights & Ratios
PEG Ratio0.23
Price to Book (P/B)0.82
Price to Sales (P/S)0.00
P/FCF Ratio-54.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetVery low leverage and a sizeable equity base reduce refinancing and solvency risk, giving management optionality to fund operations or pursue strategic initiatives without relying on high-cost debt. Over months this preserves runway and lowers capital-structure risk.
Improved Cash BurnA large reduction in cash burn and a near-flat free cash flow in FY2025 demonstrate meaningful operating-cost control vs prior year. This durable improvement extends runway, reduces near-term financing dependency, and increases time to execute on business development.
Narrowing Net LossesYear-over-year reduction in net loss signals progress on expense management or early business traction. If sustained, a continuing downward trend in losses supports a path toward break-even and improves the likelihood of eventual positive operating leverage.
Bears Say
No Reported RevenueZero reported revenue offers no evidence of product-market fit or scalable sales, making future margin and cash-flow projections highly uncertain. Over a multi-month horizon, lack of revenue is the central structural risk to achieving sustainable operations.
Ongoing Negative Cash FlowContinued operating losses and negative cash generation mean the business is not self-funding and will likely require external capital to continue. Structural dependence on funding increases execution risk and can dilute shareholders or constrain strategic options.
Negative Returns On EquityA sizable equity base that is producing negative ROE indicates capital is not being productively deployed. Persistently negative returns will erode the equity cushion if losses continue, raising longer-term concerns about capital efficiency and management allocation decisions.
TrivarX Limited News
TRI FAQ
What was TrivarX Limited’s price range in the past 12 months?
TrivarX Limited lowest share price was <AU$0.01 and its highest was AU$0.04 in the past 12 months.
What is TrivarX Limited’s market cap?
TrivarX Limited’s market cap is AU$25.38M.
When is TrivarX Limited’s upcoming earnings report date?
TrivarX Limited’s upcoming earnings report date is Aug 27, 2026 which is in 68 days.
How were TrivarX Limited’s earnings last quarter?
TrivarX Limited released its earnings results on Feb 24, 2026. The company reported -AU$0.002 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.002.
Is TrivarX Limited overvalued?
According to Wall Street analysts TrivarX Limited’s price is currently Overvalued.
Does TrivarX Limited pay dividends?
TrivarX Limited does not currently pay dividends.
What is TrivarX Limited’s EPS estimate?
TrivarX Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does TrivarX Limited have?
TrivarX Limited has 1,153,693,500 shares outstanding.
What happened to TrivarX Limited’s price movement after its last earnings report?
TrivarX Limited reported an EPS of -AU$0.002 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -8.696%.
Which hedge fund is a major shareholder of TrivarX Limited?
Currently, no hedge funds are holding shares in AU:TRI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
TrivarX Limited Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
-7.84%
Trailing 12-Months
Asset Growth
112.47%
Trailing 12-Months
Company Description
TrivarX Limited
Operating as a health technology enterprise, TrivarX Limited specializes in crafting artificial intelligence-driven, scientifically validated instruments designed for the assessment and identification of behavioral health disorders. Its market presence extends across Australia and the United States. The company delivers mental well-being provisions tailored for corporate clients through its enterprise health offerings, concurrently developing solutions for medical service providers. Established in 1987, the entity was formerly known as Medibio Limited until its rebranding as TrivarX Limited in October 2023. Its principal place of business is situated in Mount Lawley, Australia.
Technical Analysis
Resonance Health Ltd
―
Opyl Ltd.
―
MedAdvisor Limited
―
InteliCare Holdings Limited
―
PainChek Ltd
―
Options Prices
Currently, No data available
---